The aberrant PBX1 expression is associated with poor prognoses (Magnani et al., 2015), tumorigeneses (Park et al., 2008), resistance to cancer therapy (Jung et al., 2016), and poor response to induction therapy (Veselska et al., 2019). The gene discussed is PBX1; the disease is cancer.